About Dpb Pharmaceuticals Limited
Data last updated: 17 February 2026
Dpb Pharmaceuticals Limited is a public limited company based in Mumbai, Maharashtra, India. It specialises in pharmaceutical retail and distribution, a part of the broader pharmaceuticals sector. Incorporated on 20 April 2018, the company has been in operation for over 8 years.
Registered with ROC Mumbai under CIN U24304MH2018PLC308316.
Capital: an authorised share capital of ₹5.05 Cr and a paid-up capital of ₹3.13 Cr. It is led by directors including Devang Manharlal Ajmera and Piyush Manharlal Ajmera.
Last AGM: 30 September 2024. Financial statements filed for year ended 31 March 2024. Office: 308 3Rd Floor Exim Link Indira Container Yard Nr.Nahur Railway Station Bhandup W, Mumbai, Maharashtra, India – 400078.
As per the financials filed for FY 2024, the company reported a revenue of ₹223.13 Cr, a growth of 18% compared to the previous year.
The company is associated with 2 brands - Dpb Group, Dpb Antibiotics. As per MCA filings, the company has open charges of ₹74 Cr and satisfied charges of ₹10 Cr on record.
For more details, the company can be reached via its website dpbpharma.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered Address308 3Rd Floor Exim Link Indira Container Yard Nr.Nahur Railway Station Bhandup W, Mumbai, Maharashtra, India – 400078
-
IndustryPharma, Pharmaceutical Retailers & Distributors
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Associated Brands with Dpb Pharmaceuticals Limited
Dpb Pharmaceuticals Limited operates two associated brands: DPB Group and DPB Antibiotics. These brands represent Dpb Pharmaceuticals Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| DPB Group is engaged in manufacturing pharmaceutical APIs in India. | dpbpharma.com | |
| Specializes in the manufacturing and supplying of active pharmaceutical ingredients (APIs). | dpbantibiotics.com |
Competitors & Alternatives of Dpb Pharmaceuticals Limited
Brands and companies operating in the same space as Dpb Pharmaceuticals Limited include WuXi AppTec, ANI Pharmaceuticals, Aptar and 7 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
WuXi AppTec
|
Provider of CRO and CDMO services | Shanghai, China, China | 2000 |
ANI Pharmaceuticals
|
Branded and generic prescription drugs are developed, manufactured, and marketed. | Baudette, United States, United States | 1996 |
Aptar
|
Regulatory support, brand differentiation, and prototyping services are provided. | Crystal Lake, United States, United States | 1992 |
CHEPLAPHARM
|
Branded pharmaceutical products are developed, marketed, and distributed globally. | Mesekenhagen, Germany, Germany | 1998 |
Red Nucleus
|
Advisory, scientific, and medical communications provided for pharmaceutical industry. | Yardley, United States, United States | 2014 |
Ipsen
|
Biopharmaceutical company focused on developing and commercializing innovative treatments in oncology, rare disease, and neuroscience to improve patient health outcomes | - | 1929 |
Eurofins Scientific
|
Laboratory testing and contract research services are provided globally. | Luxembourg, Luxembourg, Luxembourg | 1987 |
China Medical System
|
Generic formulations including tablets, capsules, liquids, and injectables are manufactured. | Shenzhen, China, China | 1992 |
Aliada Therapeutics
|
Provider of drug research & development services for multiple therapeutic areas | Boston, United States, United States | 2021 |
Del Trade
|
Serves as a distributor of a wide range of pharmaceutical drugs. | Delhi, India, India | 2010 |
Business Activity of Dpb Pharmaceuticals Limited
Dpb Pharmaceuticals Limited is engaged in the principal business activity of trade, with detailed activities including wholesale trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | ********* |
Auditor Details of Dpb Pharmaceuticals Limited
Dpb Pharmaceuticals Limited is audited by JAYSHREE JAIN & CO. for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| JAYSHREE JAIN & CO. | blur-value | blur-value | blur-value |
Board of Directors of Dpb Pharmaceuticals Limited
Dpb Pharmaceuticals Limited is governed by 3 directors who oversee the company's operations and strategic decisions.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Devang Manharlal Ajmera | Director | 20 Apr 2018 | 8 Years 2 Months | Current |
|
Piyush Manharlal Ajmera
Also directs:
Vardhman Chemtech Limited, Dpb Antibiotics Private Limited
|
Director | 20 Apr 2018 | 8 Years 2 Months | Current |
|
Bhavin Manharlal Ajmera
Also directs:
Vardhman Chemtech Limited, Dpb Antibiotics Private Limited
|
Director | 20 Apr 2018 | 8 Years 2 Months | Current |
Financials of Dpb Pharmaceuticals Limited FY 2024 filings available
Dpb Pharmaceuticals Limited reported revenue of ₹223.13 Cr (up 18% YoY) for FY 2024. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Dpb Pharmaceuticals Limited
As of FY 2023, Dpb Pharmaceuticals Limited's shareholding pattern shows 100.00% by promoters. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Group Structure of Dpb Pharmaceuticals Limited
Dpb Pharmaceuticals Limited has 2 associated companies. This group structure data is as of FY 2023. The corporate group structure reflects Dpb Pharmaceuticals Limited's business expansion strategy and organizational complexity.
Charges & Borrowings of Dpb Pharmaceuticals Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 02 Apr 2025 | Others | ₹24 Cr | Open |
| 26 Mar 2024 | Yes Bank Limited | ₹20 Cr | Open |
| 24 Jun 2022 | Others | ₹20 Cr | Open |
| 26 Apr 2022 | The Hongkong and Shanghai Banking Corporation Limited | ₹10 Cr | Open |
| 19 Aug 2022 | Hdfc Bank Limited | ₹10 Cr | Satisfied |
Total charge records: 5 View all charges
Employees and EPFO Compliance at Dpb Pharmaceuticals Limited
View historical data on people associated with Dpb Pharmaceuticals Limited, including employment history and EPFO contributions.
Employee Count & EPFO Data of Dpb Pharmaceuticals Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Dpb Pharmaceuticals Limited
GSTIN & GST Filing Data of Dpb Pharmaceuticals Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Dpb Pharmaceuticals Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Dpb Pharmaceuticals Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Dpb Pharmaceuticals Limited
MSME Payment Delays by Dpb Pharmaceuticals Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Dpb Pharmaceuticals Limited
Subsidiaries & Group Companies of Dpb Pharmaceuticals Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Dpb Pharmaceuticals Limited with ownership details.
MCA Filings & Documents of Dpb Pharmaceuticals Limited
MCA Filings & Documents of Dpb Pharmaceuticals Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Dpb Pharmaceuticals Limited
Frequently Asked Questions about Dpb Pharmaceuticals Limited
Dpb Pharmaceuticals Limited is an active public limited company in the pharma sector based in Mumbai, Maharashtra, India. It was incorporated on 20 April 2018 (8+ years old) and is registered under CIN U24304MH2018PLC308316.
Dpb Pharmaceuticals Limited reported revenue of ₹223.13 Cr for FY 2024 (up 18.00% YoY).
The current directors of Dpb Pharmaceuticals Limited are:
The primary industry of Dpb Pharmaceuticals Limited is pharma. The company specifically operates in pharmaceutical retailers and distributors. The company is currently active in this sector.
Dpb Pharmaceuticals Limited can be reached at the registered office: 308 3Rd Floor Exim Link Indira Container Yard Nr.Nahur Railway Station Bhandup W, Mumbai, Maharashtra, India – 400078, or through the website dpbpharma.com.
The authorised capital is ₹5.05 Cr, and the paid-up capital is ₹3.13 Cr.